EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ketone Body Metabolism in Cancer-Associated Fibroblasts and FSTL3 as Prognostic and Therapeutic Determinants of Chemoradiotherapy Response in Cervical Cancer

Hua Yang, Litian Ma, Rui Ma, Dong Huang, Weiwei Li, Jianping Li, Yong Zhu, Lichun Wei, Zi Liu

Frontiers in Bioscience-Landmark · 16.10.2026 · 31 (10)

DOI: 10.31083/fbl54670 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 16.10.2026. Verfasst von Hua Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Xi'an Jiaotong University First Affiliated Hospital, 710061 Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Cancer-Associated Fibroblasts, Chemoradiotherapy, Follistatin-Related Proteins. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joint Founding Project of Innovation Research Institute, Xijing Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Concurrent chemoradiotherapy (CCRT) is a cornerstone of treatment for locally advanced cervical cancer, although many patients show a poor response. The tumor microenvironment (TME) is a key determinant of therapeutic resistance and prognosis, with the metabolic reprogramming within specific cellular subsets playing a particularly important role. However, the cellular sources of metabolic heterogeneity in cervical cancer and their clinical implications have yet to be firmly established.

Methods

An integrated analysis of single-cell RNA sequencing (scRNA-seq) datasets from eight patients cervical cancer, together with bulk RNA sequencing data retrieved from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, was conducted. Cellular heterogeneity was characterized using the Seurat and Harmony, while metabolic activity was assessed by integrating five algorithms (AUCell, UCell, singscore, ssGSEA, and AddModuleScore). The Least Absolute Shrinkage and Selection Operator (LASSO)-Cox regression was used to construct a prognostic model, which was subsequently validated in external cohorts. The functional role of the key gene FSTL3 was examined through both in vitro and in vivo experiments. Results: scRNA-seq analyses identified 10 major cell types within the cervical cancer TME. Among these, cancer-associated fibroblasts (CAFs) showed the greatest enrichment of ketone body metabolism-related gene signatures. CAFs with high enrichment of these signatures exhibited enhanced cell–cell communication and were associated with activation of the AP-1 transcription factor network. Analysis of these CAFs led to the development of a nine-gene prognostic signature (KLF4, SERPINF1, CD74, PRPS2, ERRFI1, FSTL3, SOD2, JUN, and CXCL3). A risk model based on these genes predicted survival in the TCGA training and validation sets and in independent GEO cohorts (disease-free survival in GSE44001 and overall survival in GSE52903). A nomogram combining the risk score with clinical variables showed improved predictive performance compared with either the risk score or clinical variables alone. Knockdown of FSTL3 suppressed tumor growth and enhanced sensitivity to irradiation and cisplatin in both in vitro and in vivo models, supporting its functional role in cervical cancer progression and treatment response.

Conclusion

These analyses identify a CAF population enriched in ketone body metabolism-related gene expression that may be associated with cervical cancer progression. In addition to establishing a prognostic model for further evaluation, this study identifies FSTL3 as a potential therapeutic target that warrants further mechanistic and pharmacological investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsCancer-Associated FibroblastsChemoradiotherapyFollistatin-Related ProteinsKetonesFemaleHumansKruppel-Like Factor 4AnimalsPrognosisTumor MicroenvironmentMiceGene Expression Regulation, NeoplasticCell Line, TumorMetabolic Reprogramming

Stichwörter der Autor:innen

FSTL3cancer-associated fibroblastscervical cancerketone body metabolismprognostic modeltumor microenvironment

Substanzen

Kruppel-Like Factor 4Follistatin-Related ProteinsKLF4 protein, humanKlf4 protein, mouseKetones

Autor:innen und Institutionen

  • Department of Radiation Oncology, Xi'an Jiaotong University First Affiliated Hospital, 710061 Xi'an, Shaanxi, China.
  • Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, 710032 Xi'an, Shaanxi, China.
  • Department of Traditional Chinese Medicine (Department of Integrated Traditional and Western Medicine of Oncology), Tangdu Hospital, Fourth Military Medical University, 710023 Xi'an, Shaanxi, China.
  • Shaanxi Provincial Key Laboratory of Bioelectromagnetic Detection and Intelligent Perception, 710032 Xi'an, Shaanxi, China.
  • Department of Biomedical Engineering, Fourth Military Medical University, 710032 Xi'an, Shaanxi, China.
  • Department of Radiotherapy, Baoji Central Hospital, 721008 Baoji, Shaanxi, China.

Förderung

  • Joint Founding Project of Innovation Research Institute, Xijing Hospital

Zitieren

APA

Yang, H., Ma, L., Ma, R., Huang, D., Li, W., Li, J., Zhu, Y., Wei, L., & Liu, Z. (2026). Ketone Body Metabolism in Cancer-Associated Fibroblasts and FSTL3 as Prognostic and Therapeutic Determinants of Chemoradiotherapy Response in Cervical Cancer. Frontiers in Bioscience-Landmark, 31(10). https://doi.org/10.31083/fbl54670

Vancouver

Yang H, Ma L, Ma R, Huang D, Li W, Li J, et al. Ketone Body Metabolism in Cancer-Associated Fibroblasts and FSTL3 as Prognostic and Therapeutic Determinants of Chemoradiotherapy Response in Cervical Cancer. Frontiers in Bioscience-Landmark. 2026;31(10). doi:10.31083/fbl54670

BibTeX
@article{Yang2026,
  author = {Yang, Hua and Ma, Litian and Ma, Rui and Huang, Dong and Li, Weiwei and Li, Jianping and Zhu, Yong and Wei, Lichun and Liu, Zi},
  title = {Ketone Body Metabolism in Cancer-Associated Fibroblasts and FSTL3 as Prognostic and Therapeutic Determinants of Chemoradiotherapy Response in Cervical Cancer},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2026},
  volume = {31},
  number = {10},
  doi = {10.31083/fbl54670}
}
Kostenlos starten →